EBS Q3'26 Earnings: EPS estimate is (0.39) USD

Emergent BioSolutions (EBS) is expected to report Q3'26 earnings on November 02, with projected revenue of 123.22 million USD and EPS of (0.39) USD. The company will disclose results after market close at 4:00 PM ET.

Original reporting
Published Oct 30, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
EBS Q3'26 Earnings: EPS estimate is (0.39) USD — source image
Decision brief

The 30-second read

$EBSNeutralMed
01

Why it matters

The provided consensus EPS and revenue estimates set the baseline for expectations, but the text does not add new operational, regulatory, or clinical catalysts.

02

Market read

This is an earnings-timing and consensus-expectations setup that can inform short-term positioning into the after-hours release.

03

What to watch

Actual results and guidance commentary can diverge materially from consensus; without any new company-specific catalyst, positioning risk remains high into the print.

Relevance 4/10Novelty 4/10Timing: ahead of Nov 2 after-hours earnings release

Background

The article states EBS will announce Q3'26 results on Nov 2 after the market closes, with the earnings release time given as 4:00 PM ET.

Company-level read

Ticker impact

$EBSNeutralMedium confidence
Context

EBS is scheduled to report Q3'26 results on Nov 2 after the close, with consensus EPS expected at -0.39 and revenue at $123.22M.

Expected impact

Likely volatility into the Nov 2 after-hours earnings window as the market prices the -0.39 EPS and $123.22M revenue expectations.

Evidence & confidence

The article provides the scheduled release timing and consensus estimates, but does not include any new company-specific development beyond the upcoming earnings setup.

Market effects

Biotech earnings calendar item that can affect near-term sentiment for small-cap life-sciences names, but no sector-wide catalyst is described.

Primarily US small-cap biotech earnings positioning; limited broader regional spillover implied.

No direct global macro or cross-market linkage beyond standard earnings timing.

Counterpoint

Because the piece is only a scheduled earnings setup with consensus numbers, it may not drive incremental trading beyond what the market already expects.

Key entities

  • EBS

    Emergent BioSolutions Inc., scheduled to report Q3'26 results on Nov 2 after the close.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)